Investigating the effect of Q10 in thalassemia patients treated with Iron chelators

Investigating the effect of Q10 on laboratory findings in thalassemia patients treated with Iron chelators: a double-blind clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221102056386N1

Enrollment

Registered

2023-03-03

Start date

2023-04-08

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thalassemia. Thalassemia

Interventions

Intervention 1: Intervention group: Receiving 100 mg of Q10 tablets (Provided by Shari Pharmaceutical Company) daily for 3 months to thalassemia patients treated with Iron chelators. Intervention 2: C

Eligibility

Sex/Gender

All

Age

2 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with major and intermedia beta thalassemia disease History of taking Iron chelators regularly in the last three months Age between 2 and 65 years

Exclusion criteria

Exclusion criteria: Having an active infection Existence of contraindications to the studied drugs

Design outcomes

Primary

Measure	Time frame
Glomerular filtration rate. Timepoint: At the beginning and end of the third month of using Q10. Method of measurement: Autoanalyzer device.;Blood Urea Nitrogen. Timepoint: At the beginning and end of the third month of using Q10. Method of measurement: Autoanalyzer device.;Creatinine. Timepoint: At the beginning and end of the third month of using Q10. Method of measurement: Autoanalyzer device.;Uric acid. Timepoint: At the beginning and end of the third month of using Q10. Method of measurement: Autoanalyzer device.;Pr/Cr ratio. Timepoint: At the beginning and end of the third month of using Q10. Method of measurement: Autoanalyzer device.	—

Measure

Time frame

Glomerular filtration rate. Timepoint: At the beginning and end of the third month of using Q10. Method of measurement: Autoanalyzer device.;Blood Urea Nitrogen. Timepoint: At the beginning and end of the third month of using Q10. Method of measurement: Autoanalyzer device.;Creatinine. Timepoint: At the beginning and end of the third month of using Q10. Method of measurement: Autoanalyzer device.;Uric acid. Timepoint: At the beginning and end of the third month of using Q10. Method of measurement: Autoanalyzer device.;Pr/Cr ratio. Timepoint: At the beginning and end of the third month of using Q10. Method of measurement: Autoanalyzer device.

—

Secondary

Measure	Time frame
Side effects of the studied drugs, especially those such as hypersensitivity reactions, allergies, shock, anemia, hypotension, nausea and vomiting, diarrhea, gastrointestinal spasms, weakness and lethargy, headache, and rash. Timepoint: Side effects are recorded daily in the studied groups. Method of measurement: Examining patients' files and using checklists.;Improvement of biochemical parameters of patients (Complete blood count tests, ferritin, C-reactive protein, aspartate aminotransferase, alanine transaminase, uric acid, lipid profile, albumin, fasting blood sugar). Timepoint: Beginning of study and end of study. Method of measurement: Use of cell counter and autoanalyzer device.	—

Measure

Time frame

Side effects of the studied drugs, especially those such as hypersensitivity reactions, allergies, shock, anemia, hypotension, nausea and vomiting, diarrhea, gastrointestinal spasms, weakness and lethargy, headache, and rash. Timepoint: Side effects are recorded daily in the studied groups. Method of measurement: Examining patients' files and using checklists.;Improvement of biochemical parameters of patients (Complete blood count tests, ferritin, C-reactive protein, aspartate aminotransferase, alanine transaminase, uric acid, lipid profile, albumin, fasting blood sugar). Timepoint: Beginning of study and end of study. Method of measurement: Use of cell counter and autoanalyzer device.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Malihe Mohamadzade

Bandare-abbas University of Medical Sciences

mohammadzadeh_aa@yahoo.com+98 76 3371 0373

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026